Appropriate use of proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitors for atherosclerotic cardiovascular disease: Comparison of recommendations from different guidelines or consensus around the world

Jia Ling Lin, Po Hsun Huang, Hung I. Yeh, Yi Heng Li

Research output: Contribution to journalReview articlepeer-review

2 Citations (Scopus)

Fingerprint

Dive into the research topics of 'Appropriate use of proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitors for atherosclerotic cardiovascular disease: Comparison of recommendations from different guidelines or consensus around the world'. Together they form a unique fingerprint.

Medicine & Life Sciences